Johnson & Johnson Cash on Hand 2006-2019 | JNJ

Johnson & Johnson cash on hand from 2006 to 2019. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Johnson & Johnson cash on hand for the quarter ending June 30, 2019 was $15.278B, a 15.77% decline year-over-year.
  • Johnson & Johnson cash on hand for 2018 was $19.687B, a 7.6% increase from 2017.
  • Johnson & Johnson cash on hand for 2017 was $18.296B, a 56.34% decline from 2016.
  • Johnson & Johnson cash on hand for 2016 was $41.907B, a 9.2% increase from 2015.
Johnson & Johnson Annual Cash on Hand
(Millions of US $)
2018 $19,687
2017 $18,296
2016 $41,907
2015 $38,376
2014 $33,089
2013 $29,206
2012 $21,089
2011 $32,261
2010 $27,658
2009 $19,425
2008 $12,809
2007 $9,315
2006 $4,084
2005 $16,138
Johnson & Johnson Quarterly Cash on Hand
(Millions of US $)
Q2 2019 $15,278
Q1 2019 $15,336
Q4 2018 $19,687
Q3 2018 $19,364
Q2 2018 $18,139
Q1 2018 $15,204
Q4 2017 $18,296
Q3 2017 $16,231
Q2 2017 $12,853
Q1 2017 $39,343
Q4 2016 $41,907
Q3 2016 $40,433
Q2 2016 $42,584
Q1 2016 $39,855
Q4 2015 $38,376
Q3 2015 $37,306
Q2 2015 $33,954
Q1 2015 $31,319
Q4 2014 $33,089
Q3 2014 $33,005
Q2 2014 $31,624
Q1 2014 $29,392
Q4 2013 $29,206
Q3 2013 $25,228
Q2 2013 $25,129
Q1 2013 $21,668
Q4 2012 $21,089
Q3 2012 $19,771
Q2 2012 $16,915
Q1 2012 $33,847
Q4 2011 $32,261
Q3 2011 $30,927
Q2 2011 $29,682
Q1 2011 $26,867
Q4 2010 $27,658
Q3 2010 $22,126
Q2 2010 $18,901
Q1 2010 $18,010
Q4 2009 $19,425
Q3 2009 $14,337
Q2 2009 $14,716
Q1 2009 $13,933
Q4 2008 $12,809
Q3 2008 $14,799
Q2 2008 $13,058
Q1 2008 $11,144
Q4 2007 $9,315
Q3 2007 $8,320
Q2 2007 $5,971
Q1 2007 $5,191
Q4 2006 $4,084
Q3 2006 $14,692
Q2 2006 $14,725
Q1 2006 $17,185
Q4 2005 $16,138
Q3 2005 $15,179
Q2 2005 $13,161
Q1 2005 $13,650
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $344.174B $81.581B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Roche Holding AG (RHHBY) Switzerland $241.683B 0.00
Merck (MRK) United States $212.562B 17.48
Pfizer (PFE) United States $201.220B 11.85
Novartis AG (NVS) Switzerland $197.737B 17.02
Novo Nordisk (NVO) Denmark $120.697B 21.33
AstraZeneca (AZN) United Kingdom $114.317B 22.12
Sanofi (SNY) France $111.209B 13.66
Eli Lilly (LLY) United States $108.824B 20.31
AbbVie (ABBV) United States $105.372B 8.44
GlaxoSmithKline (GSK) United Kingdom $102.412B 12.87
Bristol-Myers Squibb (BMY) United States $81.559B 11.57
Bayer (BAYRY) Germany $68.561B 9.99
H Lundbeck (HLUYY) Denmark $6.721B 9.70